Article Text

Download PDFPDF

5PSQ-124 The role of the clinical pharmacist in avoiding medication errors in a clinical research onco-haematologic unit
  1. P Garcia Ortega,
  2. E Serramontmany Morante,
  3. L Garcia Basas,
  4. P Latorre García,
  5. P Rovira Torres,
  6. L Manos Pujol,
  7. I Cidoncha Muñoz,
  8. MQ Gorgas Torner
  1. Vall d’Hebron University Hospital, Clinical Research Onco-Hematologic Pharmacy Unit, Barcelona, Spain


Background and importance The complexity in the design and execution of clinical trials has created the need to coordinate a multidisciplinary team in which the pharmacist has a fundamental role to avoid medication errors (ME).

ME are especially important in clinical trials since any minimal deviation in the protocol can lead to the patient leaving the study.

Aim and objectives To analyse the medication errors detected in the clinical trials area of the Clinical Research Onco-Hematologic Pharmacy Unit, in order to identify the points of greatest risk and establish improvement measures.

Material and methods A prospective analysis of medication errors detected during 6 months (January 2021–June 2021) was conducted by pharmacists in the Clinical Research Onco-Hematologic Pharmacy Unit in the course of their activity. At the same time, the errors detected during the validation of the medical prescriptions and during the quality control of the intravenous preparations were analysed.

Results A total of 250 errors were recorded. Most of the errors detected (n=135; 54%) originated in the prescription process, of which the most frequent were: error in the patient’s weight (31.11%), the prescription of an incorrect dose (26.67%), prescribing the wrong chemotherapy regimen (17.78%), errors in the confirmation of treatment (8.15%), and others (16.29%). In 8 (5.93%) cases, the error reached the patient. None of these caused serious consequences.

Regarding the preparation process, 115 (46%) errors were detected. 63.47% were due to errors in the conservation specifications: 57.39% storage temperature specifications and 6.08% related to photoprotection. 21.90% confusions that required a repeat of the preparation and 20% that referred to infusion systems.

Conclusion and relevance Most of the ME that occured in the Clinical Clinical Research Onco-Hematologic Pharmacy Unit are intercepted before they reach the patient. Most of them were generated in the prescription process, mainly due to an error in the patient’s weight.

The information obtained in this analysis reinforces the role of the clinical pharmacist in avoiding errors and improving measures to increase patients’ safety.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.